Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.82 |
| ▸ | RAB9A | P51151 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biochanin A, Dimethyl Ether SCHEMBL5795557 | 0.90 | CYP3A4 (1.00) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL28788159 | 0.87 | KDM4E (0.83) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL31186354 | 0.86 | SMN1; SMN2 (0.76) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL1227819 | 0.86 | SMN1; SMN2 (0.76) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL10622209 | 0.86 | EGFR (0.77) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL30288208 | 0.85 | CYP3A4 (0.81) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| 5-Hydroxy-7-Methoxyisoflavone SCHEMBL6142401 | 0.85 | RAB9A (0.83) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL7056427 | 0.85 | CYP3A4 (0.76) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL16335646 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL16335377 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4ECYP3A4SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-09-19 | — | — | US | claimed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008011083-A2 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| EP-3013331-B1 | MULTITARGET HEDGEHOG PATHWAY INHIBITORS AND THEIR USE FOR THE TREATMENT OF CERTAIN HEDGEHOG (HH)-DEPENDENT TUMORS | UNIV DEGLI STUDI DI SIENA (IT) | 2023-03-01 | — | — | EP | disclosed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20210030714-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF BRAIN DISEASES | UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2021-02-04 | — | — | US | disclosed |
| EP-3749300-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF BRAIN DISEASES | Università degli Studi di Roma "La Sapienza" (IT) | 2020-12-16 | — | — | EP | disclosed |
| CN-112004534-A | Compounds for use in the treatment of brain tumors | 罗马大学 | 2020-11-27 | — | — | CN | disclosed |
| WO-2019149962-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF BRAIN DISEASES | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2019-08-08 | — | — | WO | disclosed |
| US-10093642-B2 | Multitarget hedgehog pathway inhibitors and uses thereof | Università degli Studi di Roma “La Sapienza” (IT) | 2018-10-09 | — | — | US | disclosed |
| US-20160368886-A1 | MULTITARGET HEDGEHOG PATHWAY INHIBITORS AND USES THEREOF | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2016-12-22 | — | — | US | disclosed |
| US-20140186277-A1 | Methods and Compositions for Reducing Skin Damage | SHISEIDO CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-09-19 | — | — | US | disclosed |
| US-20110091387-A1 | METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| CN-101918037-A | Be used to reduce the method and composition of skin injury | GEN HOSPITAL CORP | 2010-12-15 | — | — | CN | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2009065141-A1 | METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008011083-A2 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368886-A1 | MULTITARGET HEDGEHOG PATHWAY INHIBITORS AND USES THEREOF | SHH, GLI1, SMO | ALDH1A1 2823/4885KDM4E 942/4885CYP3A4 4845/4885 |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | ARG2, ARG1, OTC | ALDH1A1 249/4885KDM4E 1426/4885CYP3A4 3922/4885 |
| US-10093642-B2 | Multitarget hedgehog pathway inhibitors and uses thereof | SHH, GLI1, SMO | ALDH1A1 2823/4885KDM4E 942/4885CYP3A4 4845/4885 |
| US-20210030714-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF BRAIN DISEASES | NLN, ADCYAP1R1, PYGB | ALDH1A1 1323/4885KDM4E 2941/4885CYP3A4 3645/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ALDH1A1 860/4885KDM4E 3739/4885CYP3A4 2876/4885 |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | ARG2, ARG1, OTC | ALDH1A1 292/4885KDM4E 1521/4885CYP3A4 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.